News & Analysis on Clinical Trial Services & Contract Research And Development
Prosonix has launched a new particle engineering technology in an attempt to reach the inhaled drug delivery market - at the same time the British firm has extended an agreement with UCB for the use of its existing sonocrystallisation technology.
According to a new report, the kinase-targeted drug market is set to grow from $12.7 bn (€10bn) in 2005 to $58.6bn in 2010. Cancer (mainly solid tumours) is expected to remain the dominant application throughout the forecast period.
Japanese firm Ebara and Berlin-based Capsulution NanoScience are now working together to develop a new time-controlled release technology for pharmaceuticals.
Injection molder and contract manufacturer Tech Group is relocating its Grand Rapids plant to a new molding facility in nearby Walker, Michigan, which will be expanded to cope with the high demand for medical devices and components.
Scientists have demonstrated that a tumour suppressor gene could actually stimulate tumour progression, which if confirmed, could raise possibilities of using the gene as a novel prognostic indicator of tumour aggressiveness.
BioDiscovery has released a new array module for its Imagene software that provides an advanced array-based DNA copy number analysis and visualisation tool for the drug discovery sector.